- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03487133
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
A Prospective, Multi-center, Open-label, Single-arm, Phase II Study of Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma
the efficacy and safety of bortezomib / dexamethasone combination therapy in patients with relapsed or refractory T-cell lymphoma who have failed one or more treatments.
primary purpose
1. Overall response rate
secondary purpose
- Progression-free survival and overall survival
- Disease stabilization ratio
- Duration of reaction
- Safety Profile
- Experiments on response prediction / immunological markers
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Gang Nam
-
Seoul, Gang Nam, Korea, Republic of, 676
- Samsung Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically diagnosed subcutaneous skin T-cell lymphoma based on the WHO(World Health Organization)-EORTC classification (mycosis fungoides, Sezary syndrome,primary cutaneous anaplastic large cell lymphoma,lymphomatoid papulosis,primary cutaneous peripheral T-cell lymphoma, unspecified)
- Male and female patients aged 19-80
- ECOG(Eastern Cooperative Oncology Group performance) 0~2
- Presence of measurable lesion according to ISCL(International Society for Cutaneous Lymphomas)-USCLC(United States Cutaneous Lymphoma Consortium)-EORTC(European Organization of Research and Treatment of Cancer) recommendation
- If one or more of the previous treatments fails or has recurred / progressed
- Proper function status of bone marrow, kidney, liver
- All toxic effects due to previous treatment have been resolved to CTCAE 4.03 version 1 or lower
- For pregnant women, the result of pregnancy test is negative. (The pregnant female patient should have effective contraception during the treatment period and for one month thereafter) (ie, hormonal contraceptive device, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) Men should use effective contraception during the treatment period and for three months thereafter.)
- Patients who are expected to follow and comply with the clinical trial protocol at the discretion of the tester
- Patients who voluntarily agreed to participate in this trial and signed a consent form
- Patients who agreed to donate a sample of peripheral lesions (10 unstained slides) and 3 ml of peripheral blood after baseline and cycle 8
Exclusion Criteria:
- Patients undergoing chemotherapy at the time of clinical trials
- Patients who are undergoing radiotherapy at the time of their participation in the trial or who received radiotherapy within the first 6 months of the trial. However, patients who have additional lesions elsewhere in the main lesion may be eligible for clinical trials if they have completed local radiotherapy as a palliative treatment prior to the administration of the drug, and recovered from the resulting toxicity.
- Patients with symptomatic or uncontrolled angina and congestive heart failure, arrhythmia requiring drug therapy, significant risk of clinically significant myocardial infarction within 6 months prior to participation in this trial
- Patients with stable left ventricular ejection fraction less than the normal lower limit of each organ.
- Adverse Reactions Common Terminology Criteria 4.03 In case of infection in excess of grade 2 according to the standards. Hepatitis B is allowed if there is no active replication (HBV DNA> 20,000 iU / mL associated with ALT(alanine aminotransferase) exceeding twice the normal upper limit).
- If there is active infection, including severe concomitant disease and / or active hepatitis C and human immunodeficiency virus infection
- Patients who received chemotherapy, surgical treatment (permissive for mild surgical treatment) within 4 weeks of the administration of this drug
- History of allogeneic transplantation (including hematopoietic stem cell transplantation)
- Patients with a malignant tumor other than the target disease. However, the following cases are allowed.If you have not received treatment for the tumor for at least 5 years or have no disease,Complete resection of basal cell carcinoma / squamous cell carcinoma or at least 1 year after successful treatment of cervical intraepithelial cancer
- Adverse reactions within 30 days prior to the start of screening Common Grade Criteria 4.03 Severe gastrointestinal bleeding in excess of grade 2
- The occurrence of thrombosis or embolism within 6 months before screening
- Patients with central nervous system involvement.
- Pregnant, lactating, or reproductive women who are not willing to use appropriate contraception during the trial
- Unstable conditions that may impair patient safety and compliance with the test
- Patients with seizure disorders requiring medication
- If you have substance abuse, medical, mental or social illnesses that may interfere with the patient's participation in the clinical trial or the evaluation of clinical trial results
- Patients with a history of hypersensitivity to Drug or Drug component (bortezomib, boron, mannitol, dexamethasone)
- Patients with Acute Diffuse Invasive Pulmonary Disease and Cardiovascular Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: bortezomib/dexamethasone
Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
|
Induction therapy ->1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy ->1cycle=28 days 1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate of tumor
Time Frame: Through study completion, an average of 3 years
|
Overall response rate (complete remission, partial remission) according to the ISCL-USCLC-EORTC recommendation evaluated by institutional investigators
|
Through study completion, an average of 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progressive-free survival
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months
|
the time interval between the first clinical trial dosing date and the first occurring date of tumor progression or death (due to all causes) Duration of response: The time from the first documentation of the objective tumor response to the time of disease progression or death (due to all causes)
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months
|
Disease stabilization rate
Time Frame: An average of 6 years
|
Percentage of subjects who achieved complete remission, partial remission, or stable lesions as a result of tumor response
|
An average of 6 years
|
Duration of response
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months
|
The time from the first documentation of the objective tumor response to the time of disease progression or death (due to all causes)
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 72 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Seok Jin Kim, 81, Irwon-Ro, Gangnam-Gu, Seoul, Korea 135-710
Publications and helpful links
General Publications
- (1) Bradford PT, et al. Blood 2009; 113: 5064 (2) Criscione VD, et al. Arch Dermatol 2007; 143: 854 (3) Willemze R. et al. Blood 2005; 105: 3768 (4) Li JY, et al. Cancer Manag Res 2012; 4: 75 (5) Wilcox RA. Am J Hematol 2016; 91: 152 (6) Querfeld C, et al. Blood 2014; 123: 1159 (7) Kim YH, et al. J Am Acad Dermatol 2010; 63: 975 (8) Yamamoto K, et al. J Clin Oncol 2010; 28: 1591 (9) Bose P, et al. Exp Opin Pharmacother 2014; 15: 2443 (10) Manfé V, et al. PLoS One 2013; 8: e59390 (11) Chang TP, et al. Am J Cancer Res 2013; 3: 433 (12) Chang TP, et al. J Immunol 2015; 194: 1942 (13) Ungewickell A, et al. Nat Genet 2015; 47: 1056 (14) Jagannath S, et al. Br J Haematol 2005; 129: 776 (15) Jagannath S, et al. Br J Haematol 2009; 146: 619 (16) Zinzani PL, et al. J Clin Oncol 2007; 25: 4293 (17) Kim SJ, et al. Eur J Cancer 2012; 48: 3223 (18) Moreau P, et al. Lancet Oncol 2011; 12: 431
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
- Bortezomib
Other Study ID Numbers
- 2017-02-104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and/or Refractory Cutaneous T-cell Lymphoma
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)Japan
-
National Cancer Institute (NCI)Active, not recruitingCutaneous T-Cell Lymphoma | Peripheral T-Cell Lymphoma | Mature T-cell Malignancies | Relapsed/ Refractory T-cell MalignanciesUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedRelapsed Cutaneous T Cell LymphomChina
-
Bausch Health Americas, Inc.CompletedRefractory Cutaneous T-cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Angioimmunoblastic T-Cell Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Refractory Anaplastic... and other conditionsUnited States
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
Clinical Trials on bortezomib/dexamethasone
-
National Cancer Institute (NCI)CompletedHead and Neck CancerUnited States
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Laryngeal Cancer | Oral Cancer | Carcinoma, Squamous | Pharyngeal CancerUnited States
-
Air Force Military Medical University, ChinaNot yet recruitingImmunoglobulin Light-chain Amyloidosis
-
Antengene CorporationActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.CompletedAmyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)United States
-
Janssen-Cilag International NVCompletedMultiple MyelomaFrance, Poland, Belgium, Germany, Israel, Portugal, Turkey, Finland, Sweden, Netherlands, Norway
-
Institute of Hematology & Blood Diseases Hospital...TerminatedAcquired Pure Red Cell AplasiaChina
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Tampere University HospitalTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsCompleted
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting